|
Market Closed -
Nasdaq
01:30:00 23/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 514.99 USD | +0.84% |
|
-0.87% | +13.59% |
| Market Cap | 13TCr 11TCr 11TCr 9.7TCr 18TCr 12,37500Cr 18TCr 1,27600Cr 49TCr 6,32000Cr 49TCr 48TCr 20,37300Cr | P/E 2026 * |
52.5x | P/E 2027 * | 27.7x |
|---|---|---|---|---|---|
| Enterprise Value | 13TCr 11TCr 10TCr 9.38TCr 18TCr 11,96600Cr 18TCr 1,23400Cr 48TCr 6,11100Cr 47TCr 46TCr 19,70000Cr | EV / Sales 2026 * |
9.45x | EV / Sales 2027 * | 8.38x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
London S.E.
| 0QZU | Delayed | |
|
Tradegate
| VX1 | Real-time | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
Xetra
| VX1 | Delayed | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
CBOE
| 0QZU | Real-time | |
|
CBOE
| Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +0.84% | ||
| 1 week | -0.87% | ||
| Current month | -5.42% | ||
| 1 month | -6.03% | ||
| 3 months | +14.03% | ||
| 6 months | +13.43% | ||
| Current year | +13.59% |
| 1 week | 501.01 |  | 525.97 |
| 1 month | 501.01 | | 560.25 |
| Current year | 412.27 | | 560.25 |
| 1 year | 374.17 | | 560.25 |
| 3 years | 341.85 | | 560.25 |
| 5 years | 176.36 | | 560.25 |
| 10 years | 71.46 | | 560.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/04/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 10/04/2019 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 01/01/1998 |
Jeffrey Leiden
CHM | Chairman | 70 | 01/05/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 18/06/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/08/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 27/08/26 | Don | Director | -6,000 | 0.0024% | ||
| 21/07/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.84% | -0.87% | +34.42% | +45.36% | 13TCr | |
| +0.45% | +2.80% | +55.61% | +112.70% | 1,03800Cr | |
| -0.10% | +1.08% | +52.78% | +66.52% | 65TCr | |
| +0.28% | +1.31% | +19.21% | +72.85% | 47TCr | |
| -0.19% | +0.75% | +37.34% | +45.03% | 36TCr | |
| +0.28% | +2.23% | +19.12% | +25.62% | 27TCr | |
| +0.89% | +4.26% | +12.10% | +16.41% | 26TCr | |
| +4.34% | +7.53% | +43.74% | +52.27% | 21TCr | |
| -0.46% | -7.70% | -33.40% | -59.71% | 18TCr | |
| +1.40% | +4.28% | +33.82% | +102.83% | 19TCr | |
| Average | +0.75% | +0.77% | +27.47% | +47.99% | 37.45TCr | |
| Weighted average by Cap. | +0.62% | +1.36% | +36.51% | +65.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.32TCr 1.16TCr 1.09TCr 992.93Cr 1.86TCr 1,26600Cr 1.86TCr 13TCr 5.04TCr 65TCr 4.97TCr 4.87TCr 2,08500Cr | 1.45TCr 1.27TCr 1.19TCr 1.09TCr 2.05TCr 1,39100Cr 2.05TCr 14TCr 5.53TCr 71TCr 5.46TCr 5.34TCr 2,28900Cr |
| Net income | 253.49Cr 221.52Cr 208.2Cr 190Cr 356.59Cr 24TCr 356.66Cr 2.5TCr 964.21Cr 12TCr 951.94Cr 931.08Cr 40TCr | 483.12Cr 422.2Cr 396.81Cr 362.11Cr 679.62Cr 46TCr 679.75Cr 4.76TCr 1.84TCr 24TCr 1.81TCr 1.77TCr 76TCr |
| Net Debt | -427.75Cr -373.81Cr -351.33Cr -320.61Cr -601.72Cr -41TCr -601.84Cr -4.22TCr -1.63TCr -21TCr -1.61TCr -1.57TCr -67TCr | -754.02Cr -658.94Cr -619.31Cr -565.16Cr -1.06TCr -72TCr -1.06TCr -7.43TCr -2.87TCr -37TCr -2.83TCr -2.77TCr -1,18700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | $514.99 | +0.84% | 13,83,962 |
| 21/26/21 | $510.72 | +0.47% | 9,06,681 |
| 18/26/18 | $508.34 | -1.55% | 24,34,832 |
| 17/26/17 | $516.34 | +0.60% | 9,00,049 |
| 16/26/16 | $513.26 | -0.27% | 6,38,512 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
